Literature DB >> 15799029

Osteoprotegerin (OPG) is localized to the Weibel-Palade bodies of human vascular endothelial cells and is physically associated with von Willebrand factor.

A C W Zannettino1, C A Holding, P Diamond, G J Atkins, P Kostakis, A Farrugia, J Gamble, L B To, D M Findlay, D R Haynes.   

Abstract

Recent studies demonstrate roles for osteoprotegerin (OPG) in both skeletal and extra-skeletal tissues. Although its role in preventing osteoclast (OC) formation and activity is well documented, emerging evidence suggests a role of OPG in endothelial cell survival and the prevention of arterial calcification. In this communication, we show that vascular endothelial cells in situ, and human umbilical vein endothelial cells (HUVEC) in vitro, express abundant OPG. In HUVEC, OPG co-localizes with P-selectin and von Willebrand factor (vWF), within the Weibel-Palade bodies (WPB). Treatment of HUVEC with the pro-inflammatory cytokines, tumor necrosis factor (TNF)-alpha and IL-1beta, resulted in mobilization from the WPBs and subsequent secretion of OPG protein into the culture supernatant. Furthermore, TNF-alpha treatment of HUVEC resulted in a sustained increase in OPG mRNA levels and protein secretion over the 24-h treatment period. Reciprocal immunoprecipitation experiments revealed that while not associated with P-Selectin, OPG is physically complexed with vWF both within the WPB and following secretion from endothelial cells. Interestingly, this association was also identified in human peripheral blood plasma. In addition to its interaction with vWF, we show that OPG also binds with high avidity to the vWF reductase, thrombospondin (TSP-1), raising the intriguing possibility that OPG may provide a link between TSP-1 and vWF. In summary, the intracellular localization of OPG in HUVEC, in association with vWF, together with its rapid and sustained secretory response to inflammatory stimuli, strongly support a modulatory role in vascular injury, inflammation and hemostasis. (c) 2005 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15799029     DOI: 10.1002/jcp.20354

Source DB:  PubMed          Journal:  J Cell Physiol        ISSN: 0021-9541            Impact factor:   6.384


  45 in total

1.  A revised model for the secretion of tPA and cytokines from cultured endothelial cells.

Authors:  Laura Knipe; Athinoula Meli; Lindsay Hewlett; Ruben Bierings; John Dempster; Paul Skehel; Matthew J Hannah; Tom Carter
Journal:  Blood       Date:  2010-06-10       Impact factor: 22.113

2.  Mutations in osteoprotegerin account for the CCAL1 locus in calcium pyrophosphate deposition disease.

Authors:  C J Williams; U Qazi; M Bernstein; A Charniak; C Gohr; E Mitton-Fitzgerald; A Ortiz; L Cardinal; A T Kaell; A K Rosenthal
Journal:  Osteoarthritis Cartilage       Date:  2018-03-22       Impact factor: 6.576

Review 3.  Harnessing the versatile role of OPG in bone oncology: counterbalancing RANKL and TRAIL signaling and beyond.

Authors:  Maria V Deligiorgi; Mihalis I Panayiotidis; John Griniatsos; Dimitrios T Trafalis
Journal:  Clin Exp Metastasis       Date:  2019-10-01       Impact factor: 5.150

Review 4.  Functional architecture of Weibel-Palade bodies.

Authors:  Karine M Valentijn; J Evan Sadler; Jack A Valentijn; Jan Voorberg; Jeroen Eikenboom
Journal:  Blood       Date:  2011-01-25       Impact factor: 22.113

Review 5.  Relationship between serum RANKL and RANKL in bone.

Authors:  D M Findlay; G J Atkins
Journal:  Osteoporos Int       Date:  2011-08-18       Impact factor: 4.507

6.  Meta-analysis of genome-wide association studies identifies two loci associated with circulating osteoprotegerin levels.

Authors:  Johnny S H Kwan; Yi-Hsiang Hsu; Ching-Lung Cheung; Josée Dupuis; Aude Saint-Pierre; Joel Eriksson; Samuel K Handelman; Aaron Aragaki; David Karasik; Peter P Pramstaller; Charles Kooperberg; Andrea Z Lacroix; Martin G Larson; Kam-Shing Lau; Mattias Lorentzon; Irene Pichler; Pak C Sham; Daniel Taliun; Liesbeth Vandenput; Douglas P Kiel; Andrew A Hicks; Rebecca D Jackson; Claes Ohlsson; Emelia J Benjamin; Annie W C Kung
Journal:  Hum Mol Genet       Date:  2014-07-30       Impact factor: 6.150

7.  Osteoprotegerin contributes to the metastatic potential of cells with a dysfunctional TSC2 tumor-suppressor gene.

Authors:  Wendy K Steagall; Gustavo Pacheco-Rodriguez; Connie G Glasgow; Yoshihiko Ikeda; Jing-Ping Lin; Gang Zheng; Joel Moss
Journal:  Am J Pathol       Date:  2013-07-16       Impact factor: 4.307

8.  Factor VIII-von Willebrand factor complex inhibits osteoclastogenesis and controls cell survival.

Authors:  Marc Baud'huin; Laurence Duplomb; Stéphane Téletchéa; Céline Charrier; Mike Maillasson; Marc Fouassier; Dominique Heymann
Journal:  J Biol Chem       Date:  2009-09-16       Impact factor: 5.157

9.  Osteoprotegerin inhibits vascular calcification without affecting atherosclerosis in ldlr(-/-) mice.

Authors:  Sean Morony; Yin Tintut; Zina Zhang; Russell C Cattley; Gwyneth Van; Denise Dwyer; Marina Stolina; Paul J Kostenuik; Linda L Demer
Journal:  Circulation       Date:  2008-01-02       Impact factor: 29.690

10.  Breast cancer cells stimulate osteoprotegerin (OPG) production by endothelial cells through direct cell contact.

Authors:  Penny E Reid; Nicola J Brown; Ingunn Holen
Journal:  Mol Cancer       Date:  2009-07-15       Impact factor: 27.401

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.